Fierce Biotech Next Gen 2023
Attending this event?
Tuesday, June 13

10:00am EDT

Panel: What will the next decade hold for cell and gene therapies?
A new wave of cell therapies and genetic medicines are revolutionizing how we treat and potentially cure certain diseases. While new therapies are gaining steam and starting to change patients’ lives, reimbursement and access challenges remain. Experts on this panel will discuss today’s challenges and what the future holds for potentially lifesaving gene editing tools and cell therapies.  

avatar for Gabrielle Masson

Gabrielle Masson

Staff Writer, Fierce Biotech
Gabrielle Masson is a staff writer for Fierce Biotech. Prior to Fierce, she worked at Becker's Hospital Review for nearly three years, where she reported on public health and the pandemic. Gabrielle graduated from the University of Wisconsin-Madison in 2019 after studying creative... Read More →

avatar for Zach Roberts, M.D., Ph.D

Zach Roberts, M.D., Ph.D

EVP of R&D and Chief Medical Officer, Allogene
Zach is an immunologist and board-certified oncologist with extensive experience in clinical oncology and a strong passion for making a transformative impact on the lives of people with cancer. While at Kite Pharma, Zach was instrumental in the development and execution of the ZUMA... Read More →
avatar for Dan Kirby

Dan Kirby

Chief Commercial Officer, Orca Bio
Dan leads Orca Bio’s commercial strategy for our cell therapy platform products. His areas of focus include market engagement, reimbursement landscape evaluation, value story creation, key opinion leader outreach, and communications. Previously, Dan was Chief Commercial Officer... Read More →
avatar for Michael Klichinsky

Michael Klichinsky

Co-Founder & Chief Scientific Officer, Carisma Therapeutics
Mike is a co-inventor of the CAR-Macrophage technology and a scientific co-founder of Carisma Therapeutics Inc. In his role as Chief Scientific Officer, he oversees the research & discovery efforts of the company. Mike developed CAR-Macrophages during his doctoral thesis under the... Read More →
avatar for Warner Biddle

Warner Biddle

Head of Commercial, Kite
Warner Biddle joined Kite in 2020, where he currently serves as Global Head of Commercial.  A seasoned healthcare executive with a successful industry track record of growth and business development, Warner was Vice President for the Breast/Gynecologic and Skin Cancer Franchises... Read More →

Tuesday June 13, 2023 10:00am - 11:00am EDT

11:00am EDT

Partner Keynote: Cytiva
avatar for Linda Mathiasson

Linda Mathiasson

Strategic Customer Leader, Nucleic Acid Therapeutics, Cytiva
Linda Mathiasson is the strategic customer collaboration lead in Cytiva's Nucleic Acid Therapeutics business unit, responsible for technical and scientific engagement and collaborations with customers in the global RNA application community. Linda has more than 20 years of experience... Read More →

Tuesday June 13, 2023 11:00am - 11:20am EDT

11:20am EDT

Executive Interview with Phil Dormitzer
avatar for Kevin Dunleavy

Kevin Dunleavy

Staff Writer, Fierce Pharma
Kevin Dunleavy is a staff writer for Fierce Pharma. He joined the Fierce team after working 26 years as a newspaper sportswriter. He compiles Fierce Pharma’s COVID Tracker and writes about manufacturing and other topics. Kevin is a longtime resident of Northern Virginia and a graduate... Read More →
avatar for Phil Dormitzer

Phil Dormitzer

Senior Vice President and Global Head of Vaccines Research and Development, GSK
Dr. Dormitzer joined GSK as Global Head of Vaccines Research and Development in December 2021. At GSK, he oversees a broad portfolio of Vaccine R&D programs. Previously, he was Chief Scientific Officer for Viral and RNA Vaccines at Pfizer, where he led programs that included the Pfizer-BioNTech... Read More →

Tuesday June 13, 2023 11:20am - 11:40am EDT

11:40am EDT

Accelerate your Central Lab Value Chain: Flexible Solutions to Reach Patients Faster
With the ongoing complexities of clinical treatment journeys, central labs remain a vital component in the supply chain for developing and distributing personalized lifesaving therapies. To design resilient, future-focused logistic solutions that operate at lightspeed, providers must understand the unique lab products and processes to ensure final mile delivery to and from patients across the globe.

Join patient-centric supply chain expert Marco Hogenboom for an insightful discussion on how to accelerate the delivery of advanced therapies in an unpredictable environment through supply chain customization from clinical to commercialization.

This presentation will explore:
• Key trends, global forecasts and growth drivers in the complex and highly competitive central labs market
• Centralized and regionalized approaches that mobilize your ability to pivot to the needs of the patient and client
• Advanced technology impacting the distribution of personalized therapies and enhancing study outcomes including mRNA vaccines, AI and data-based evidence• Ensuring cold chain integrity and 24/7 real-time traceability with temperature-controlled packaging solutions that are changing the game
• Actionable lessons learned and best practices to drive efficiency and advance the scale and availability of precision medicine
• Looking ahead: changes to regulatory framework, industry demand and patient needs

avatar for Marco Hogenboom

Marco Hogenboom

Vice President Global Clinical Logistics, Marken
As Vice President of Global Clinical Logistics at Marken, Marco Hogenboom leverages over 25 years of experience in specialized logistics to drive business growth, expand service lines and increase operational efficiency throughout the EMEA region. He has held a variety of cross-functional... Read More →

Tuesday June 13, 2023 11:40am - 12:00pm EDT

12:00pm EDT

Lunch Break
Tuesday June 13, 2023 12:00pm - 1:00pm EDT

1:00pm EDT

Accelerating the Path to Market for Emerging Biotech
Early-stage biotech companies historically have had limited options to get their first asset to market. In most cases, they lose ownership and control of their asset by pursuing deals with larger partners or take upon themselves massive financial risk to invest in becoming a fully integrated company. In this session, we’ll discuss how some biotechs are flipping these traditional models to their advantage, empowering themselves to chart their own future, minimize launch risk, and maximize asset value.

avatar for Lee Taurman

Lee Taurman

EVP - Global Head of Syneos One, Syneos Health
Lee has 20+ years of experience in the life sciences industry spanning strategy and operations in both internal and management consulting roles. He currently leads the Syneos One group. His group is responsible for designing and developing innovative solutions that integrate Syneos... Read More →

Tuesday June 13, 2023 1:00pm - 1:20pm EDT

1:20pm EDT

Panel: The future of drug launches
Launching a new drug is far from straightforward, and it’s becoming increasingly difficult to craft and execute a successful launch strategy. How are companies navigating the challenges and approaching launches differently? A panel of industry experts will dive into that question and share the latest winning strategies

avatar for Ben Adams

Ben Adams

Senior Editor, Fierce Healthcare & Life Sciences
Ben Adams is a business, science and healthcare journalist who has worked as an editor for the UK publication Pharmafocus, as a group editor for Pharmaceutical Marketing Europe, as well as a features and news writer for the BMJ and the Pharmaceutical Journal. He has an especial interest... Read More →

avatar for Lynn Fenicchia

Lynn Fenicchia

SVP and Head of US Medical Specialties Business Unit, Astellas
Lynn Fenicchia is Senior Vice President and Head of US Medical Specialties Business Unit at Astellas Pharma, Inc., responsible for leading Astellas’ US commercial activities for marketed products in the urology, anti-infectives and hospital business units.  Lynn is a member of... Read More →
avatar for Lynn Price

Lynn Price

Vice President of Insights, Spherix
Lynn Price is an accomplished insights expert and trusted advisor to leading life sciences organizations and drug manufacturers.  Lynn is currently the Vice President of Insights for Spherix Global Insights. She is a recognized authority in the fields of life sciences & immunology... Read More →
avatar for Clayton Tolley

Clayton Tolley

President & CEO, Brandsymbol
Clayton began his branding career in 1993 at Addison Whitney (AW) as the 9th employee hired. In 4 years, he became President and CEO. During his tenure as President and CEO, Clayton led the business’ transition to online safety testing and commercial research, a revolutionary step... Read More →

Tuesday June 13, 2023 1:20pm - 2:20pm EDT

2:20pm EDT

Executive Interview with Antoine Papiernik
avatar for Max Bayer

Max Bayer

Staff Writer, Fierce Healthcare & Life Sciences
Max Bayer is a staff writer for Fierce Biotech. He joined after more than three years at CBS News, two of which were spent covering the twists and turns of the COVID-19 pandemic, from infection trends to CDC guidelines. He graduated from the University of Wisconsin-Madison in 2018... Read More →
avatar for Antoine Papiernik

Antoine Papiernik

Chairman and Managing Partner, Sofinnova Partners
Antoine Papiernik is Chairman and Managing Partner at Sofinnova Partners, which he joined in 1997. He has been an initial investor and active board member in a number of public companies, including Actelion, ProQR, Shockwave Medical, NovusPharma (sold to CTI), and Movetis (sold... Read More →

Tuesday June 13, 2023 2:20pm - 2:40pm EDT

2:40pm EDT

Streamlining therapeutic mAbs discovery with optimized and automated transient expression workflow
Therapeutic mAbs continues to be a rapidly growing field and a promising solution to address many unmet medical needs. To meet market demands, mAb developers are actively looking for more efficient and robust production platforms to reduce timelines and overall development costs. Throughput, productivity, and scalability of the expression platform as well as availability of well-documented production cell lines are key selection criteria when initiating a mAbs campaign. To this end, Gibco™ ExpiCHO™ and Expi293™ Expression Systems are complete platforms that can speed up mAbs discovery by enabling rapid, high-yield, and scalable protein production from mammalian (ExpiCHO™ and Expi293™) cells. The Thermo Scientific™ Cytomat™ series is the leading brand of incubators in lab automation. TRUE orbital shaking ensures superior cell growth for cells in suspension, which is critical for mAb candidate expression. These proven solutions back by a team of SME enable mAb developers to get to key milestones faster.

avatar for Matt McKenna

Matt McKenna

Field Application Scientist, Thermo Fisher Scientific
Born and raised in Massachusetts, Matt has spent the last 18yrs working in the Cambridge area in both large pharma and small biotech settings. While mostly focused on transient protein expression, Matt also has extensive experience in developing stable cell lines expressing monoclonal... Read More →
avatar for Dieter Wagner

Dieter Wagner

Product Manager, Thermo Fisher Scientific
Dieter received his degree in Automation from the THM Friedberg and worked in sales and product management roles in several different industries including vacuum technology, optical disc, semiconductor, and organic materials. During this time Dieter developed a passion for biotechnology... Read More →

Tuesday June 13, 2023 2:40pm - 3:00pm EDT

3:00pm EDT

Panel: The ABCs of ADCs: What's next?
Antibody-drug conjugates have been around for more than 20 years and there's now more than a dozen on the market worldwide. So why all of a sudden are Big Pharmas scrambling to strike new deals in the ADC space? Billions of dollars in licensing deals have been put on the line in the past year. This panel will dive into the new frontier of ADCs: where they are headed in the clinic—and whether they have a future beyond cancer.

avatar for Angus Liu

Angus Liu

Senior Staff Writer, Fierce Pharma, Questex Life Sciences
Angus is a senior staff writer with Questex’s Life Sciences group. He earned his Master’s at Northwestern University’s Medill School of Journalism, where he worked as a health reporter besides learning pertinent skills in magazine editing and interactive production. Prior to... Read More →

avatar for Scott Peterson

Scott Peterson

SVP Head of Research, Seagen
avatar for Timothy B. Lowinger, PhD

Timothy B. Lowinger, PhD

Chief Science and Technology Officer, Mersana
Since joining Mersana, when it was a nascent start-up, Tim has served as Chief Scientific Officer, and in 2019 was named Chief Science and Technology Officer. Since the beginning, he has led all of Mersana’s discovery efforts and is a co-inventor of all of our innovative ADC... Read More →
avatar for Mark Rutstein, M.D.

Mark Rutstein, M.D.

Head of Global Oncology Clinical Development, Daiichi Sankyo
As Head of Global Oncology Clinical Development, Mark and his team are responsible for the successful clinical development of the Daiichi Sankyo global oncology portfolio – ensuring oncology development has a strong talent base and a culture that values each individual. In his... Read More →

Tuesday June 13, 2023 3:00pm - 4:00pm EDT

Filter sessions
Apply filters to sessions.